{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:58:39Z","timestamp":1792645119906,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T00:00:00Z","timestamp":1714176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T00:00:00Z","timestamp":1714176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s12282-024-01586-2","type":"journal-article","created":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T20:01:21Z","timestamp":1714161681000},"page":"717-725","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Adverse effects of tamoxifen treatment on bone mineral density in premenopausal patients with breast cancer: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"31","author":[{"given":"Soo Jin","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihwan David","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanpyo","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Young","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Sung","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,27]]},"reference":[{"key":"1586_CR1","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1093\/jnci\/93.13.979","volume":"93","author":"P Eifel","year":"2001","unstructured":"Eifel P, et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1\u20133, 2000. J Natl Cancer Inst. 2001;93:979\u201389. https:\/\/doi.org\/10.1093\/jnci\/93.13.979.","journal-title":"J Natl Cancer Inst"},{"key":"1586_CR2","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2174\/1574884711308020006","volume":"8","author":"PY Maximov","year":"2013","unstructured":"Maximov PY, Lee TM, Jordan VC. The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice. Curr Clin Pharmacol. 2013;8:135\u201355. https:\/\/doi.org\/10.2174\/1574884711308020006.","journal-title":"Curr Clin Pharmacol"},{"key":"1586_CR3","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/S0140-6736(97)11423-4","volume":"351","author":"Early Breast Cancer Trialists Collaborative Group","year":"1998","unstructured":"Early Breast Cancer Trialists Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351:1451\u201367.","journal-title":"Lancet"},{"key":"1586_CR4","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/s0140-6736(11)60993-8","volume":"378","author":"C Davies","year":"2011","unstructured":"Davies C, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:771\u201384. https:\/\/doi.org\/10.1016\/s0140-6736(11)60993-8.","journal-title":"Lancet"},{"key":"1586_CR5","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.31.18_suppl.5","author":"R Gray","year":"2013","unstructured":"Gray R, et al. aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6953 women with early breast cancer. J Clin Oncol. 2013. https:\/\/doi.org\/10.1200\/jco.2013.31.18_suppl.5.","journal-title":"J Clin Oncol"},{"key":"1586_CR6","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/s0140-6736(12)61963-1","volume":"381","author":"C Davies","year":"2013","unstructured":"Davies C, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381:805\u201316. https:\/\/doi.org\/10.1016\/s0140-6736(12)61963-1.","journal-title":"Lancet"},{"key":"1586_CR7","doi-asserted-by":"publisher","first-page":"135","DOI":"10.6026\/97320630012135","volume":"12","author":"S Ali","year":"2016","unstructured":"Ali S, et al. Molecular mechanisms and mode of tamoxifen resistance in breast cancer. Bioinformation. 2016;12:135\u20139. https:\/\/doi.org\/10.6026\/97320630012135.","journal-title":"Bioinformation"},{"key":"1586_CR8","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/nejm199811263392207","volume":"339","author":"CK Osborne","year":"1998","unstructured":"Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998;339:1609\u201318. https:\/\/doi.org\/10.1056\/nejm199811263392207.","journal-title":"N Engl J Med"},{"key":"1586_CR9","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/s1470-2045(02)00711-8","volume":"3","author":"RM O'Regan","year":"2002","unstructured":"O\u2019Regan RM, Jordan VC. The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators. Lancet Oncol. 2002;3:207\u201314. https:\/\/doi.org\/10.1016\/s1470-2045(02)00711-8.","journal-title":"Lancet Oncol"},{"key":"1586_CR10","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1093\/jnci\/90.9.704","volume":"90","author":"TJ Powles","year":"1998","unstructured":"Powles TJ, et al. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst. 1998;90:704\u20138. https:\/\/doi.org\/10.1093\/jnci\/90.9.704.","journal-title":"J Natl Cancer Inst"},{"key":"1586_CR11","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1200\/jco.1996.14.1.78","volume":"14","author":"TJ Powles","year":"1996","unstructured":"Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol. 1996;14:78\u201384. https:\/\/doi.org\/10.1200\/jco.1996.14.1.78.","journal-title":"J Clin Oncol"},{"key":"1586_CR12","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3389\/fonc.2019.00359","volume":"9","author":"WJ van Weelden","year":"2019","unstructured":"van Weelden WJ, Massuger L, Pijnenborg JMA, Romano A. Anti-estrogen treatment in endometrial cancer: a systematic review. Front Oncol. 2019;9:359. https:\/\/doi.org\/10.3389\/fonc.2019.00359.","journal-title":"Front Oncol"},{"key":"1586_CR13","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1200\/jco.1994.12.5.992","volume":"12","author":"B Kristensen","year":"1994","unstructured":"Kristensen B, et al. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. J Clin Oncol. 1994;12:992\u20137. https:\/\/doi.org\/10.1200\/jco.1994.12.5.992.","journal-title":"J Clin Oncol"},{"key":"1586_CR14","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/bjc.1997.105","volume":"75","author":"T Saarto","year":"1997","unstructured":"Saarto T, et al. Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens. Br J Cancer. 1997;75:602\u20135. https:\/\/doi.org\/10.1038\/bjc.1997.105.","journal-title":"Br J Cancer"},{"key":"1586_CR15","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1210\/jcem.83.4.4688","volume":"83","author":"MB Marttunen","year":"1998","unstructured":"Marttunen MB, Hietanen P, Tiitinen A, Ylikorkala O. Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients. J Clin Endocrinol Metab. 1998;83:1158\u201362. https:\/\/doi.org\/10.1210\/jcem.83.4.4688.","journal-title":"J Clin Endocrinol Metab"},{"key":"1586_CR16","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/s0169-6009(08)80220-6","volume":"22","author":"RL Ward","year":"1993","unstructured":"Ward RL, Morgan G, Dalley D, Kelly PJ. Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women. Bone Miner. 1993;22:87\u201394. https:\/\/doi.org\/10.1016\/s0169-6009(08)80220-6.","journal-title":"Bone Miner"},{"key":"1586_CR17","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.1200\/jco.2004.08.148","volume":"22","author":"A Sverrisd\u00f3ttir","year":"2004","unstructured":"Sverrisd\u00f3ttir A, Fornander T, Jacobsson H, von Schoultz E, Rutqvist LE. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. J Clin Oncol. 2004;22:3694\u20139. https:\/\/doi.org\/10.1200\/jco.2004.08.148.","journal-title":"J Clin Oncol"},{"key":"1586_CR18","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s10549-020-05566-w","volume":"180","author":"M Kim","year":"2020","unstructured":"Kim M, et al. Changes in bone mineral density during 5 years of adjuvant treatment in premenopausal breast cancer patients. Breast Cancer Res Treat. 2020;180:657\u201363. https:\/\/doi.org\/10.1007\/s10549-020-05566-w.","journal-title":"Breast Cancer Res Treat"},{"key":"1586_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339: b2535. https:\/\/doi.org\/10.1136\/bmj.b2535.","journal-title":"BMJ"},{"key":"1586_CR20","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22:153\u201360. https:\/\/doi.org\/10.1136\/ebmental-2019-300117.","journal-title":"Evid Based Ment Health"},{"key":"1586_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","volume":"36","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36:1\u201348.","journal-title":"J Stat Softw"},{"key":"1586_CR22","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1002\/cncr.28302","volume":"119","author":"RR Love","year":"2013","unstructured":"Love RR, et al. Bone mineral density following surgical oophorectomy and tamoxifen adjuvant therapy for breast cancer. Cancer. 2013;119:3746\u201352. https:\/\/doi.org\/10.1002\/cncr.28302.","journal-title":"Cancer"},{"key":"1586_CR23","first-page":"331","volume":"49","author":"K Hojan","year":"2013","unstructured":"Hojan K, Milecki P, Moli\u0144ska-Glura M, Roszak A, Leszczy\u0144ski P. Effect of physical activity on bone strength and body composition in breast cancer premenopausal women during endocrine therapy. Eur J Phys Rehabil Med. 2013;49:331\u20139.","journal-title":"Eur J Phys Rehabil Med"},{"key":"1586_CR24","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1093\/annonc\/mdr600","volume":"23","author":"F Nuzzo","year":"2012","unstructured":"Nuzzo F, et al. Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study. Ann Oncol. 2012;23:2027\u201333. https:\/\/doi.org\/10.1093\/annonc\/mdr600.","journal-title":"Ann Oncol"},{"key":"1586_CR25","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1210\/jc.2010-2582","volume":"96","author":"RA Anderson","year":"2011","unstructured":"Anderson RA, Cameron DA. Pretreatment serum anti-m\u00fcllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. J Clin Endocrinol Metab. 2011;96:1336\u201343. https:\/\/doi.org\/10.1210\/jc.2010-2582.","journal-title":"J Clin Endocrinol Metab"},{"key":"1586_CR26","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/sj.bjc.6605460","volume":"102","author":"NL Henry","year":"2010","unstructured":"Henry NL, et al. Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy. Br J Cancer. 2010;102:294\u2013300. https:\/\/doi.org\/10.1038\/sj.bjc.6605460.","journal-title":"Br J Cancer"},{"key":"1586_CR27","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1200\/jco.2005.02.7102","volume":"25","author":"MF Gnant","year":"2007","unstructured":"Gnant MF, et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol. 2007;25:820\u20138. https:\/\/doi.org\/10.1200\/jco.2005.02.7102.","journal-title":"J Clin Oncol"},{"key":"1586_CR28","doi-asserted-by":"publisher","first-page":"366","DOI":"10.3389\/fonc.2020.00366","volume":"10","author":"J Lee","year":"2020","unstructured":"Lee J, et al. Effect of tamoxifen on the risk of osteoporosis and osteoporotic fracture in younger breast cancer survivors: a nationwide study. Front Oncol. 2020;10:366. https:\/\/doi.org\/10.3389\/fonc.2020.00366.","journal-title":"Front Oncol"},{"key":"1586_CR29","doi-asserted-by":"publisher","first-page":"100254","DOI":"10.1016\/j.jbo.2019.100254","volume":"18","author":"U Stumpf","year":"2019","unstructured":"Stumpf U, Kostev K, Kyvernitakis J, B\u00f6cker W, Hadji P. Incidence of fractures in young women with breast cancer\u2014a retrospective cohort study. J Bone Oncol. 2019;18:100254. https:\/\/doi.org\/10.1016\/j.jbo.2019.100254.","journal-title":"J Bone Oncol"},{"key":"1586_CR30","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/s1470-2045(21)00758-0","volume":"23","author":"R Bradley","year":"2022","unstructured":"Bradley R. Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. Lancet Oncol. 2022;23:382\u201392. https:\/\/doi.org\/10.1016\/s1470-2045(21)00758-0.","journal-title":"Lancet Oncol"},{"key":"1586_CR31","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1056\/nejm199203263261302","volume":"326","author":"RR Love","year":"1992","unstructured":"Love RR, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med. 1992;326:852\u20136. https:\/\/doi.org\/10.1056\/nejm199203263261302.","journal-title":"N Engl J Med"},{"key":"1586_CR32","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/s0002-9343(99)80251-4","volume":"99","author":"AB Grey","year":"1995","unstructured":"Grey AB, et al. The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women. Am J Med. 1995;99:636\u201341. https:\/\/doi.org\/10.1016\/s0002-9343(99)80251-4.","journal-title":"Am J Med"},{"key":"1586_CR33","first-page":"273","volume":"4","author":"A Parfitt","year":"1980","unstructured":"Parfitt A. Morphologic basis of bone mineral measurements: transient and steady state effect of treatment in osteoporosis. Miner Electorlyte Metab. 1980;4:273\u201387.","journal-title":"Miner Electorlyte Metab"},{"key":"1586_CR34","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/bf01807038","volume":"41","author":"JD Sibonga","year":"1996","unstructured":"Sibonga JD, Evans GL, Hauck ER, Bell NH, Turner RT. Ovarian status influences the skeletal effects of tamoxifen in adult rats. Breast Cancer Res Treat. 1996;41:71\u20139. https:\/\/doi.org\/10.1007\/bf01807038.","journal-title":"Breast Cancer Res Treat"},{"key":"1586_CR35","doi-asserted-by":"publisher","first-page":"R111","DOI":"10.1530\/joe-19-0077","volume":"241","author":"SK Ramchand","year":"2019","unstructured":"Ramchand SK, Cheung YM, Yeo B, Grossmann M. The effects of adjuvant endocrine therapy on bone health in women with breast cancer. J Endocrinol. 2019;241:R111-r124. https:\/\/doi.org\/10.1530\/joe-19-0077.","journal-title":"J Endocrinol"},{"key":"1586_CR36","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1093\/clinchem\/45.8.1359","volume":"45","author":"NB Watts","year":"1999","unstructured":"Watts NB. Clinical utility of biochemical markers of bone remodeling. Clin Chem. 1999;45:1359\u201368.","journal-title":"Clin Chem"},{"key":"1586_CR37","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1359\/jbmr.041007","volume":"20","author":"E Barrett-Connor","year":"2005","unstructured":"Barrett-Connor E, et al. Osteoporosis and fracture risk in women of different ethnic groups. J Bone Miner Res. 2005;20:185\u201394. https:\/\/doi.org\/10.1359\/jbmr.041007.","journal-title":"J Bone Miner Res"},{"key":"1586_CR38","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3389\/fendo.2015.00024","volume":"6","author":"A Zengin","year":"2015","unstructured":"Zengin A, Prentice A, Ward KA. Ethnic differences in bone health. Front Endocrinol (Lausanne). 2015;6:24. https:\/\/doi.org\/10.3389\/fendo.2015.00024.","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-024-01586-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-024-01586-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-024-01586-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T02:08:03Z","timestamp":1719108483000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12282-024-01586-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,27]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["1586"],"URL":"https:\/\/doi.org\/10.1007\/s12282-024-01586-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1822599\/v1","asserted-by":"object"}]},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,27]]},"assertion":[{"value":"3 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}